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METHODOLOGY ARTICLE

Open Access

Modeling measurement error in tumor
characterization studies
Cyril Rakovski1,4, Daniel J Weisenberger2,3, Paul Marjoram1, Peter W Laird2,3 and Kimberly D Siegmund1*

Abstract
Background: Etiologic studies of cancer increasingly use molecular features such as gene expression, DNA
methylation and sequence mutation to subclassify the cancer type. In large population-based studies, the tumor
tissues available for study are archival specimens that provide variable amounts of amplifiable DNA for molecular
analysis. As molecular features measured from small amounts of tumor DNA are inherently noisy, we propose a
novel approach to improve statistical efficiency when comparing groups of samples. We illustrate the phenomenon
using the MethyLight technology, applying our proposed analysis to compare MLH1 DNA methylation levels in
males and females studied in the Colon Cancer Family Registry.
Results: We introduce two methods for computing empirical weights to model heteroscedasticity that is caused
by sampling variable quantities of DNA for molecular analysis. In a simulation study, we show that using these
weights in a linear regression model is more powerful for identifying differentially methylated loci than standard
regression analysis. The increase in power depends on the underlying relationship between variation in outcome
measure and input DNA quantity in the study samples.
Conclusions: Tumor characteristics measured from small amounts of tumor DNA are inherently noisy. We propose
a statistical analysis that accounts for the measurement error due to sampling variation of the molecular feature
and show how it can improve the power to detect differential characteristics between patient groups.

Background
The molecular heterogeneity of cancer is explored through
a variety of technologies. With the decreasing costs of
technology, in combination with the development of
methods for the analysis of archival specimens, it is now
feasible to conduct molecular analysis in large epidemiologic studies. Of primary interest are the population-based
frequencies of different molecular features, and whether
they vary by patient characteristics. However, an issue that
arises with the analysis of archival specimens is the varying
quantity and quality of DNA material that they can provide. Real-time PCR using TaqMan®-based fluorescence
chemistry is one technology often used for sensitive detection for measuring a number of such molecular features.
Understanding the impact that a low amount of amplifiable material has on the stability of the lab measurement
is important to efficient statistical analysis.
* Correspondence: kims@usc.edu
1
Department of Preventive Medicine, USC Keck School of Medicine, Los
Angeles, California 90089-9176, USA
Full list of author information is available at the end of the article

In cancer studies of archival specimens, tumors are sectioned, allowing them to be subject to many different
types of molecular studies. Consequently, DNA is
extracted from only a portion of the tumor, and fragmented prior to lab analysis. Both the heterogeneity in the
tumor cell population, as well as the uncertainty due to
sampling, will influence the estimate of the outcome measure and its stability. The issue of tumor heterogeneity is
well-appreciated among researchers; the epigenetic variation of the pure tumor cell population is obscured by the
inclusion of infiltrating cells in the tissue sample. However,
it is not the impact of mixture cell populations that we discuss. Instead we focus on the second factor, one which is
present even for populations of a single cell type, variation
due to low amounts of amplifiable input DNA, or equivalently, small sample size. The precision of each lab measurement, reflecting the uncertainty due to sampling DNA
fragments, typically goes unreported. We illustrate the
effect of this uncertainty on the variance of the outcome
measure, and propose new methods that incorporate the
sampling uncertainty into the statistical analysis.

© 2011 Rakovski et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
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The issue of sampling variation from the molecular
analysis of archival tissues first came to our attention in
a study of MLH1 methylation in the Colon Cancer
Family Registry (C-CFR) [1]. In the C-CFR, MLH1 DNA
methylation was measured from paraffin-embedded sections for over 1,200 colorectal tumors using the highly
sensitive MethyLight technology [2]. MethyLight utilizes
TaqMan-based, real-time PCR technology, which can
provide an approximate measure of the amount of
methylated DNA from a gene-specific MethyLight reaction and the amount of bisulfite-converted DNA using a
control reaction, from the number of PCR cycles, or C
(t) value. High quantities of DNA require fewer PCR
cycles to reach a detection threshold above background
and measure molecular features (low C(t)), whereas low
quantities of DNA require more PCR cycles (high C(t)).
In the C-CFR study we saw great variability in the ALU
C(t) levels across tumors, indicating a wide variation in
amount of DNA input available for molecular analysis.
However, it is not standard to report the distribution of
the C(t) level for the control reaction in molecular studies [3,4] and without this information, it is unclear
whether samples negative for DNA methylation truly
lack methylation, or whether they lack a sufficient
amount of DNA to detect it.
Figure 1 shows a schema illustrating how DNA features are studied using MethyLight technology. A sample of DNA consists of a collection of DNA fragments,
obtained from pooling the DNA from a number of cells.
In our example, grey balls denote segments of DNA
containing the sequence encoding ALU repetitive elements. These sequences occur frequently throughout
the genome and help us quantify the amount of DNA
present in each sample. The black and white balls represent DNA methylation states from the DNA target
sequence of interest; black denotes fully methylated
MLH1 promoter/5’ gene region and white denotes
otherwise. When DNA methylation is analyzed using
MethyLight, measures from an experimental sample are
compared to a reference, where the reference sample is
treated with M.SssI methylase, an enzyme which methylates all CpGs and therefore converts white balls to
black balls. The outcome measurement is the percent of
methylated reference (PMR), which can be viewed as
the ratio of the methylated alleles in the tumor and
reference samples adjusted (by scaling) for the different
input DNA quantities and multiplied by 100 (Figure 1C,
see Methods section for details). High PMR values
denote high levels of concordant DNA methylation in
the target sequence while PMR values of zero represent
none detectable. When the quantity of input DNA from
a tumor harbouring DNA methylation is inadequate,
PMR values can have very large variance, erroneously
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resulting in PMR ratios of 0 (false-negatives) or ratios
greater than 100. Variable levels of input DNA quantity
are illustrated in Figure 1B.
By simulating the DNA sampling process, we illustrate
the effect of quantity of amplifiable input DNA on the
sampling variation in PMR value, and show that the variation of PMR increases with decreasing DNA quantity. For
testing differential DNA methylation between groups, we
propose a novel weighted regression approach, which uses
as weights the inverse variance estimates of PMR as a
function of a surrogate measure for DNA quantity. For the
Colon CFR study of MLH1 methylation using MethyLight,
we use the ALU C(t) value as the surrogate variable. Similarly, the use of A260nm-absorbance measurements may
also provide an estimation of the amount of input DNA
available in DNA methylation-based assays. Here, we present a simulation study to compare the newly proposed
approach to a standard analysis that ignores measurement
error due to sampling genomes. We then apply the different statistical approaches to real data from the Colon CFR.

Methods
PMR values using MethyLight

The PMR is defined as follows:
B
PMR = rG × 100
B r
G
where B and Br are the numbers of methylated alleles
for the tumor and reference samples, respectively, and G
and Gr are the corresponding DNA quantities. The letters B and G remind us of the black and grey balls
described in Figure 1. The PMR value can be re-written
as the ratio of the methylated alleles in the tumor and
reference samples adjusted (by scaling) for the different
DNA quantities (=B/Br × (Gr/G × 100)). A natural probabilistic model for the PMR variable is a scaled ratio of
two binomial variates, where the scaling ratio is based
on estimates of DNA quantity. Because the DNA is fragmented, the total number of genomes is not measured
directly; instead, the amount of input DNA is quantified
by studying interspersed repeat elements occurring
throughout the genome, and scaling the genome to the
number of measured repeats. We use the repetitive element ALU for this purpose [5].
We illustrate, through simulation, the variation in
PMR as a function of DNA quantity for thousands of
tumors (Figure 2). The data are simulated to mimic the
process of sampling from the collection of DNA fragments in each sample. Let h denote the number of haploid genomes, and p the proportion of a genomic target
that is methylated. The total number of DNA fragments
in each sample is G = h × f, the product of the number
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Figure 1 Illustration of measuring DNA methylation using the MethyLight technology. A) Example DNA from an experimental sample and
an M.SssI-treated control sample. In the M.SssI-treated control sample all unmethylated MLH1 molecules become methylated. B) Sampling of
DNA fragments. A large number of fragments sampled results in a very low real-time PCR cycle threshold (ALU C(t) value). A very small number
of fragments sampled results in a high ALU C(t) value. C) The formula to compute Percent Methylated Reference (PMR), a ratio of methylated
alleles in the experimental sample (black balls) over the quantity of input DNA (grey balls) in the experimental and reference samples.

of haploid genomes, h, times f, the number of DNA
fragments per genome. Then, the number of methylated
alleles, B for the tumor sample is simulated from a
Binomial distribution with sample size G, and a methylation frequency of p/f, the proportion of DNA methylation at our genomic target scaled to the number of
fragments per genome. In the M.SssI-treated control
sample, we assume that the target of interest is methylated in every genome (p = 1). Then the number of
methylated alleles, B r , is simulated from a Binomial

distribution with sample size Gr, and DNA methylation
frequency 1/f. We describe in the results section what
happens if this assumption is not met and the DNA is
not fully converted (p < 1). Previous research using
MethyLight to measure the number of repetitive element ALU fragments, suggests that we can use f = 104
fragments per genome [5], giving us a DNA methylation
frequency of p/10 4 in the tumor sample and 1/104 in
the fully methylated control. Based on a supplementary
study designed and conducted by our lab (see
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C) P~Beta(3,12)
E(P)=.2
V(P)=.01
2
Figure 2 Scatterplot of simulated data showing Percent Methylated Reference (PMR) against C(t) value for different true methylation
proportions, p. A) p = 0.2, B) p = 0.8, C) P ~ Beta(3,12). Grey lines in figures in the left column show the true methylation proportion (or its
average), and grey dots in figures in the right column show the average PMR grouped by category of input DNA quantity.

Additional file 1), we estimated that our reference samples contained 5,500 genomes. Using these as input, we
simulated PMR values as follows:
B
(h × 104 )
PMRsim = r
× 100
B
(5500 × 104 )
where h is randomly sampled from a lognormal distribution, to mimic the distribution found in the Colon
CFR study. The PMR is zero if and only if B = 0, which
happens with probability Pr(B = 0) = (1-p)h. For p > 0,
as the amount of input DNA approaches 0, Pr(B = 0) ®
1, causing an excess of PMRs = 0 and a high false-negative rate of detection.
Differential DNA methylation analysis

We propose a novel weighted regression approach to
study the association between exposure and PMR value,

where the weights are based on an empirical estimate of
the variance of PMR as a function of a surrogate measure for DNA quantity. This allows us a quantitative
approach to handling measurement error from including
samples with low amounts of DNA input in the analysis,
beyond a simple inclusion/exclusion filter of the data.
Two approaches to computing weights are presented. In
the first, the data are divided into categories defined by
quantiles of the surrogate variable for DNA quantity,
and the variance in PMR is estimated for each category.
In the second, we order the PMR measures by increasing value of the surrogate and compute the variance of
the PMRs for sliding windows. We used different numbers of categories and window sizes in simulated data
and found that for a sample size of 200, grouping the
data by quintiles, with 40 observations in each category,
gave good power to detect differential DNA methylation,
while allowing us to control the false-positive rate. For
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populations. This variation is modelled using a Beta
distribution with mean of 0.2 and variance of 0.01, a
uni-modal distribution skewed to the right. The rightmost column in Figures 2A-C show boxplots of the
PMR values by decile of DNA quantity. The grey dots
give the estimate of the mean PMR for each decile, and
show that there is no bias in estimating the average
PMR as a function of DNA quantity. The decreasing
size of the boxes shows the decreased variance of the
PMR value with increasing DNA quantity. If the reference sample is not fully methylated, a bias is introduced
and the PMR values are overestimated and the variances
inflated (results not shown).
Figure 3 shows the standard deviation of the PMR
values estimated by decile of DNA quantity for the three
scenarios in Figure 2. Here we see that the standard
deviation is not only a function of DNA quantity, but
also of the proportion of methylated alleles. The higher
the true proportion of methylated alleles, the greater the
variation in PMR values for any quantity of DNA. This
relationship is a consequence of the Binomial variance
for the number of methylated molecules in the numerator of the PMR formula and that we are analyzing fragmented DNA. Locus-specific methylation frequencies of
0.2 and 0.8 in genomes correspond to frequencies of 2e-5
and 8e-5 in fragmented genomes (= p/104). Interestingly,
if we compare the variation for the two models with
mean methylation proportions of 0.2, we see that for
tumors with large quantities of DNA (e.g. >100 genomes), the standard deviation curve becomes flat when
there is population-level variation in the proportion of
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Results
Figure 2 shows the pronounced effect of the DNA quantity on the variation in PMR measures for proportions
of methylated alleles of 0.2 and 0.8. In Figures 2A and
2B, the proportion of methylated alleles is the same for
all tumors sampled. All of the variation in PMR is due
to sampling DNA fragments. In Figure 2C, the proportion of methylated alleles varies among individual
tumors, reflecting the variation that occurs in human

0

20

SD(PMR)

the second approach, we chose a window size of 41 so
that there were approximately the same numbers of
observations per group as for our categorical approach.
When possible, we centered the window around the
observation of interest and computed the variance
including the 20 observations ranked just above and the
20 ranked just below the observation of interest (ranking
based on the surrogate variable for DNA quantity). For
the 20 highest and lowest ranked observations for which
we could not center the window, we computed variance
using the 41 top-most, or bottom-most, observations,
respectively. For each observation, the inverse variance
for that quintile of DNA quantity, or window, provides
the weights in a weighted least squares (WLS) regression. We refer to the two WLS approaches as WLS-Q
and WLS-W, depending on whether the weights are
estimated using quintiles of DNA quantity, or a window,
respectively.
In a simulation study, the test size and power to detect
differential DNA methylation between groups of tissues
are compared. In order to present results on an absolute
scale, we report results using cut-offs based on the simulated DNA quantity. This allows us to interpret the results
in terms of the biologically relevant scale of genome
equivalents, instead of indirectly through a surrogate variable. However, the conclusions remain unchanged if a surrogate variable is used instead. The two WLS approaches
are compared to three alternate approaches that use
ordinary least squares (OLS). The first OLS approach uses
the raw PMR data as the outcome (PMR), the second uses
a transformed PMR that is meant to remove the skew (ln
(PMR+1)), and the third approach filters the data and only
analyzes PMRs from samples that exceed some minimum
number of genome equivalents (PMR[h > threshold]). We
consider thresholds of 1 and 10 genome equivalents. The
number 10 genomes is chosen by inspection of Figure 2C,
recognizing that the variance in the outcome measure
begins to increase dramatically when 10 or fewer genomes
are sampled. We also consider 1 genome equivalent as an
intermediate value between a threshold of 10 and not
using any threshold at all. The thresholding approach is
also an implementation of weighted regression, with
weights of 1 or 0 depending on whether the DNA quantity
is above or below the defined threshold.
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log10 Genomes

Figure 3 Plot of Standard Deviation of simulated PMR by
decile of input DNA quantity. p = true methylation proportion.
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methylated alleles. This suggests that the population-level
variation overwhelms the variation at the tumor level due
to sampling DNA fragments. However, for tumors with
very little DNA (e.g. <3 genomes), the curves are approximately the same, suggesting that the sampling variation
at the tumor-level overwhelms the variation at the population-level.
The Colon CFR data displayed in Figure 4 show similar relationships between PMR and DNA quantity, when
using ALU C(t) value as a surrogate for DNA quantity.
The ALU C(t) value, the number of PCR amplification
cycles needed to reach a specific PCR amplification
threshold of detectability, is inversely associated with
quantity of input DNA. High ALU C(t) values reflect
samples with low quantities of input DNA (many

A)

b

c d

e

B)
StDev(MLH1 PMR)

a

amplification cycles needed) whereas low ALU C(t)
values reflect samples with large quantities of input
DNA (few amplification cycles needed) (see Additional
file 1 for details.) The earlier result that PMR variance
decreases with increasing DNA quantity (Figure 3), and
the inverse relationship between DNA quantity and
ALU C(t) value, suggests that PMR variance increases
with increasing ALU C(t) value. This is the relationship
observed in the Colon CFR data (Figure 4B).
We used a simulation study to compare the power and
false-positive rates of the different statistical analysis
methods. The settings are selected to resemble the distributions we observed in our experimental data. Figure 4A
shows the distribution of PMR values for the C-CFR
experimental data by quintile of ALU C(t) value, our

C)
b

d

e

c

MLH1 PMR

a

4
Figure 4 DNA methylation of MLH1 in the Colon-CFR. A) Scatterplot of MLH1 Percent Methylated Reference (PMR) against ALU C(t) value for
198 MSI-H colon cancer samples from Seattle. (a)-(e) Histograms of the PMR values by 5 quintiles of ALU C(t). B) a plot of SD of MLH1 PMR by
quintile of ALU C(t) (grey bars) and by sliding windows (black circles). C) Back-to-back histograms of the MLH1 PMR in females and males for 198
MSI-H tumors from the Colon CFR (Seattle site). One sample with a PMR = 302 lies outside the range of the figure. Black dots denote the overall
mean (including the sample not displayed.)
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surrogate for DNA quantity. The distribution of
PMR values among samples with high DNA quantity
(Figure 4A, histogram (a)) appears to come from a mixture distribution with a large fraction of tumors
unmethylated, and a mean of about 0.45 among the
tumors positive for DNA methylation. Our simulations
include both pure Beta distributions to describe the
underlying population distribution of methylation proportions, but also Beta-Bernoulli mixtures where a fraction of samples have undetectable DNA methylation.
We tested the different regression approaches under the
null hypothesis for six different distributions (Figure 5).
Four different distributions are used to capture features
related to possible skewness from an underlying Beta distribution in the population. In the last two scenarios (c.i, c.
ii), we mimic the Beta-Bernoulli distribution observed in
the C-CFR by using the Beta distributions from scenarios
b.i and b.ii, with the addition of a Bernoulli variable that
independently assigns samples to the positively methylated
or unmethylated fractions; the probability a tumor has
positive methylation is 67%. We sampled DNA quantities
(on the log10 scale) using a lognormal distribution. Let h
be a random deviate from a lognormal distribution with
mean of 0 and standard deviation of 0.75 (on the log
scale). The log10 DNA quantity was equal to 2.74 - h. This
distribution caps the maximum number of genomes at
550, with 23% of the samples having less than 10 genomes,
and 9% having less than 1 genome. The shape of the distribution was chosen to match the shape observed in our
epidemiologic study.
Each data set contains 200 tumors, with sample size
ratios in two groups of 1:1, 1:2, and 2:1. We ran 10,000
replicates to estimate false-positive rates for a 5% significance level. For sample sizes of 100 in each group, the
false-positive rates show that all tests achieve the nominal 5% significance level (Figure 5). Similar findings
were observed for sample size ratios of 1:2 or 2:1
(results not shown).
We compared power for nine two-sample distributions
with unequal means in the methylation proportion. The
distributions of the true methylation proportion are
described in Table 1 (see also Additional file 2). The
means and variances of the Beta distributions for tumors
with detectable MLH1 DNA methylation, the Bernoulli
probability that a tumor has MLH1 DNA methylation,
and the differences in overall means and variances
between the two groups are provided. Scenarios a and b
consider pure Beta distributions, with scenarios for equal
variances that are small (scenario i), equal variances that
are large (scenario ii), and a larger variance occurring
with the larger mean (scenario iii). Scenario c shows a
Beta-Bernoulli mixture, where the Beta distribution with
higher mean has the greater number of tumors that have
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positive methylation. This same effect observed here has
also been reported by others [1,6].
Figure 6a.i shows the empirical power for the six analytic approaches in our simulations. In scenario a.i, the true
DNA methylation proportions are simulated from Beta
distributions with means of 0.2 and 0.27 (difference =
0.07) and variances of 0.01. The power to detect differential DNA methylation is 56% if we analyze the raw PMR
values using ordinary least squares, and only 41% if using
the log-transformed data. However, the power improves
to 88% using either weighted least squares approach,
WLS-Q or WLS-W. The analysis that omits data based
on a threshold for DNA quantity shows intermediate
power. The power is 76% after omitting tumors with less
than one genome equivalent and 86% after omitting
tumors with less than 10 genomes.
For all scenarios, we find the power for the WLS-Q and
WLS-W approaches to be very similar (Figure 6). They
both outperform the OLS analysis of the raw PMR measure for all instances, and they outperform the analysis of
the log-transformed data for all but one example. The
most improvement in power occurs when the mode is
non-zero. For Beta distributions with low mean and high
variance, the distribution appears exponential near zero
with skew to the right. For this situation (Additional file 2,
box a.ii), OLS using the log-transformation turns out to be
slightly more powerful than the WLS approach on the
untransformed data (Figure 6, Barplot a.ii). However,
further analysis suggests that the best approach for this
situation is to perform weighted regression on the logtransformed data. The power for WLS-W on the logtransformed PMR values is 0.62, whereas it was only 0.51
using OLS. Finally, the OLS method that excludes data
based on a threshold for DNA quantity often outperforms
the other OLS methods. The optimal threshold depends
on the distribution of DNA methylation in the population.
These results show that it is advantageous to exclude samples with low quantities of DNA with a smaller sample
size remaining for statistical analysis than treating them
equally to low-variance (high-quality) measures.
MLH1 analysis in Colon CFR Study

We report results for a set of 198 microsatellite instable
(MSI-H) tumors from patients recruited at the Fred
Hutchinson Cancer Research Center, Seattle, Washington C-CFR site. This subset is selected because very few
methylated samples were observed in the other MSI
categories and because Seattle is the site that recruited
the largest proportion of MSI-H cases among all of the
participating C-CFR sites. This sample set showed a
median ALU C(t) of 19.8 with an interquartile range
16.9 to 22.0. Applying the results from the supplementary study (see Additional file 1), we estimate that half
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Figure 5 Histograms showing distributions of true methylation proportions and estimates of false-positive rates (FPR) for six
simulation scenarios. Estimates of FPR from 10,000 replicate data sets of 200 tumors (100 each group).

Table 1 The distribution of methylation proportion by patient subgroup (Group 1, Group 2), in the simulation study
Bernoulli
Proportion

Beta
distribution

1

2

Mean

Var

Scenario

(Group 1,
Group 2)

(Group 1,
Group 2)

(Group 1,
Group 2)

Difference in
Overall Means

Difference in
Overall Vars3

a.i

(1,1)

(0.2, 0.27)

0

(0.01, 0.01)

0.07

a.ii

(0.04, 0.04)

0.07

0

a.iii

(0.01, 0.04)

0.07

0.3

(0.4, 0.47)

(0.01, 0.01)
(0.04, 0.04)

0.07
0.07

0
0

(0.01, 0.04)

0.07

0.3

(0.4, 0.47)

(0.01, 0.01)

0.13

0.01

c.ii

(0.04, 0.04)

0.13

0.01

c.iii

(0.01, 0.04)

0.13

0.02

b.i
b.ii
b.iii
c.i

1
2
3

(0.5,0.7)

The probability that the true methylation proportion is positive
Distribution of the true methylation proportion in methylated tumors
Estimated from the data.
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a.iii
a.iii

WLS-S
WLS-W

WLS-Q
WLS-Q

PMR
PMR[h>10]
[h>10]

PMR
PMR[h>1]
[h>1]

c.iii
c.iii
c.iii

PMR
PMR
ln(PMR+1)
ln(PMR+1)
PMR [h>1]
PMR [h>1]
PMR [h>10]
PMR [h>10]
WLS-Q
WLS-Q
WLS-W
WLS-S
WLS-S

PMR
PMR
ln(PMR+1)
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Figure 6 The simulated power comparing the six analysis methods: PMR, ln(PMR+1), PMR[h > 1], PMR[h > 10], WLS-Q and WLS-W (1000
replicate data sets, N = 200 tumors total) under nine simulation scenarios.

of the tumors provided at least 46 genomes for molecular analysis (interquartile range: 15-204 genomes), 25%
provided less than 15 genomes and 10% less than six
genomes.
Poynter et al. (2008) found a number of variables
associated with MLH1 DNA methylation in MSI-H
tumors. Here, we performed the five analyses above to
study the association between MLH1 DNA methylation
and sex. Figure 4C shows back-to-back histograms of
the PMR values in males and females. In their analysis,

Poynter et al. (2008) excluded samples with an ALU C
(t) above 24. The threshold was selected empirically by
trying to maximize sample size while maintaining sensitivity to detect DNA methylation. Applying the three
OLS methods PMR, ln(PMR+1), PMR[ct < 24], we estimated p-values of: 0.001, 5.4 × 10-5, 0.001, respectively.
Because of the mode occurring at zero, it is not surprising that the analysis of the log-transformed data provides the most statistically significant result. Using WLS
on the raw PMR measures we estimate p-values of 3.2 ×
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10 -4 , and 2.5 × 10 -4 , for the WLS-Q and WLS-W
approaches, respectively. The p-values became more statistically significant when performed on the log-transformed data, 5.5 × 10-5, and 4.3 × 10-5. This suggests
that for data with a mode of zero, the WLS approach is
more sensitive when conducted on the log-transformed
data.

Discussion
As molecular technologies have evolved and costs have
dropped, the evaluation of tumor heterogeneity is now feasible in large population-based epidemiology studies. In
such studies, having small amounts of input DNA in a
subset of the samples has the potential to obscure results
if not properly analyzed. Poynter et al. (2008) recognized
this issue. Viewing ALU C(t) as a surrogate measure of
DNA quantity, they eliminated samples with high ALU C
(t), or equivalently low quantity input DNA, from their
statistical analysis. Their approach is equivalent to a
weighted regression analysis, with weights of 1 for measures from tumors with DNA quantity above a fixed
threshold and 0 otherwise. We propose a more flexible
WLS regression approach to incorporate variation due to
sampling from small quantities of tumor DNA. The
approach uses empirically derived weights by using the
inverse variance of PMR as a function of a surrogate measure of DNA quantity. There may be more than one
approach to quantify DNA for this purpose. For example,
A260nm absorbance measurements may also be used. The
method requires stable estimates of variance obtained
from large sample sizes, making it both feasible and practical in large epidemiology studies.
Several gene expression microarray studies have also
used weighted regression to account for variable data quality [7-9]. They use the large number of genes measured on
a single array to capture information on quality, and do
not limit the quality to only one aspect such as DNA
quantity. In our application only one gene region is measured, and quality is estimated by the variance in the measure as a function of quantity of input DNA analyzed.
In a simulation study, we find that a WLS approach has
better power to detect differential DNA methylation
between groups of patient samples than standard methods
that ignore the variation due to measuring small quantities
of DNA. When the data have a mode at zero with skew to
the right, the most powerful approach is to perform a
WLS regression on the log-transformed data. Slightly less
powerful than the WLS-Q and WLS-W approaches is the
OLS approach that simply excludes samples with low
DNA quantity. As described earlier, this is also a WLS
approach, with weights of 0 and 1, and by itself always
outperforms OLS on the raw PMR values. We show that
it can be possible to select a good threshold based on plotting the variation in the outcome measure as a function of
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a surrogate measure for DNA quantity. Nevertheless, a
more quantitative model for the weights can show higher
power than this dichotomous weighting scheme.
The difference in power between OLS and WLS
approaches will depend on the distribution of DNA quantity and its association with other study variables.
Throughout all our analyses, the DNA quantity distribution followed a log-normal distribution (on the log10 scale)
with 9% of the samples having less than one genome
equivalent of input DNA. This distribution can be
expected to vary from study to study. If all tumors have
large quantities of DNA, the variation due to sampling is
negligible compared to the population-level variation in
methylation proportions; in this case, the unweighted and
weighted regressions will perform similarly. For the level
of population-variation used in our simulations, the variation due to sampling DNA overwhelms the populationlevel variation somewhere between 1 and 10 genomes. In
our simulation study, even a naïve weighted regression
approach that omits 20% of the data with low DNA quantities is more powerful than the standard regression analysis, despite the reduction in sample size. However, when
group variances are homogeneous, it appears that an
approach that estimates weights in a continuous range
between 0 and 1 is preferred to one that simply excludes
samples using a threshold.
Overall, we saw little difference between the WLS-Q and
WLS-W methods. This is presumably a function of sample
size, and larger sample sizes may allow us to see an
improvement when using local windows. Our simulation
study was performed using a sample size based on the
Colon CFR study (N = 200), however the approaches
might also be applicable for smaller sample sizes. The stability will depend on how reliably the variances can be
estimated from the data, and for this we used a window
size of 40 observations. This seemed to be the minimum
window size that would allow us to control the type I
error. An analysis of 100 observations and window size of
20 resulted in an inflated type I error, however a sample
size of 120 observations and window size of 40 did not.
The potential to identify differences between the two
weighted regression approaches (WLS-Q/WLS-W) will
also depend on the empirical association between variance
of our outcome measure and DNA quantity. The smoothing method is likely only to show greater power if the variation in outcome measure changes across a range of
DNA quantities in a way that we cannot capture by a discrete distribution. For our Colon CFR data set, it appears
that the discrete distribution is sufficient.
The weighted regression approach assumes that the variation in PMR due to low DNA input is independent of
other study variables. For the multi-center C-CFR study,
the ALU C(t) distribution, our surrogate measure for DNA
quantity, was independent of patient-level variables such
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as sex and age of disease onset, but varied between C-CFR
centers. Since the sampling design also varied by center,
this could complicate the analysis in ways that are beyond
the scope of this report.
Finally, despite the fact that our experimental data
appeared to be from a continuous distribution that
included an excess of values at zero, we chose to ignore
the discrete nature of the data at zero and only evaluate
regression models for a continuous variable. One could
propose the use of a two-degree of freedom test to
simultaneously examine the difference in proportions of
tumors with detectable DNA methylation, as well as the
difference in means levels for those tumors. However,
previous work has found that when the differences in
means and proportions occur in the same directions, as
is the situation for our data, the one degree of freedom
test from an analysis of the quantitative variable is more
powerful [10]. This improvement occurs because the difference in the overall mean for the two groups is larger
than the difference among the positive tumors only with
fewer degrees of freedom tested. The only instance in
which a two degree of freedom test is more powerful
than the one degree of freedom test is when the difference in fractions of tumors having DNA methylation
and the difference of the means for those fractions,
occur in opposite directions. The latter situation is not
observed in our data, supporting our choice for using
regression models for continuous outcomes.
An alternate approach, and one often taken for DNA
methylation data, is to dichotomize the quantitative
measures into “methylated” and “non-methylated” fractions. However, when a subset of tumors contains low
quantities of DNA, the ability to detect DNA methylation at a target site within a tumor decreases, resulting
in false-negative outcomes. In this situation, the mean
methylation fraction is no longer unbiased as DNA
quantity decreases, and instead underestimates of the
methylation fraction are obtained. Thus for dichotomous data, our approach does not provide unbiased
estimates of the fraction of tumors methylated and
further research on how to weight the analysis for this
situation is still needed.

Conclusions
In molecular analysis of tumor tissue, the variation in features measured is a combination of the population-level
(subject-to-subject) variation in tumor characteristic as
well as the individual-level (within-tumor) variation due to
sampling genomic DNA. When large amounts of genomic
DNA are used for molecular analysis, the features are well
measured and the variation in measures reflects population-level variation. However, as the amount of input
DNA decreases, the molecular features under study are
measured with error. They can be missed (false-negatives)
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or appear as outliers beyond the normal range of the data.
A careful statistical analysis will want to consider the sampling variation introduced at the tumor-level due to low
quantities of input DNA.

Additional material
Additional file 1: Inverse relationship between ALU C(t) value and
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proportions under 9 alternative hypotheses. Figure displaying the
distribution of the simulated data under the 9 chosen alternative
hypotheses.
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